PubMed Journals Articles About "Late John Mendlein Joins Reinventing Biotech Lineup April" RSS

10:26 EDT 1st April 2015 | BioPortfolio

Late John Mendlein Joins Reinventing Biotech Lineup April PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Late John Mendlein Joins Reinventing Biotech Lineup April articles that have been published worldwide.

More Information about "Late John Mendlein Joins Reinventing Biotech Lineup April" on BioPortfolio

We have published hundreds of Late John Mendlein Joins Reinventing Biotech Lineup April news stories on BioPortfolio along with dozens of Late John Mendlein Joins Reinventing Biotech Lineup April Clinical Trials and PubMed Articles about Late John Mendlein Joins Reinventing Biotech Lineup April for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Late John Mendlein Joins Reinventing Biotech Lineup April Companies in our database. You can also find out about relevant Late John Mendlein Joins Reinventing Biotech Lineup April Drugs and Medications on this site too.

Showing "Late John Mendlein Joins Reinventing Biotech Lineup April" PubMed Articles 1–25 of 3,300+

Extremely Relevant

Biotech drugs too little, too late for Ebola outbreak.

Suspect Filler Similarity in Eyewitness Lineups: A Literature Review and a Novel Methodology.

Eyewitness lineups typically contain a suspect (guilty or innocent) and fillers (known innocents). The degree to which fillers should resemble the suspect is a complex issue that has yet to be resolved. Previously, researchers have voiced concern that eyewitnesses would be unable to identify their target from a lineup containing highly similar fillers; however, our literature review suggests highly similar fillers have only rarely been shown to have this effect. To further examine the effect of highly simil...

Relevant

Double-Blind Photo Lineups Using Actual Eyewitnesses: An Experimental Test of a Sequential Versus Simultaneous Lineup Procedure.

Eyewitnesses (494) to actual crimes in 4 police jurisdictions were randomly assigned to view simultaneous or sequential photo lineups using laptop computers and double-blind administration. The sequential procedure used in the field experiment mimicked how it is conducted in actual practice (e.g., using a continuation rule, witness does not know how many photos are to be viewed, witnesses resolve any multiple identifications), which is not how most lab experiments have tested the sequential lineup. No signi...

Reinventing tech transfer.

Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL.

Current HIV-1 vaccines based on the HIV-1 envelope glycoprotein spike (Env), the only relevant target for broadly neutralizing antibodies, are unable to induce protective immunity. Env immunogenicity can be enhanced by fusion to costimulatory molecules involved in B cell activation, such as APRIL and CD40L. Here, we found that Env-APRIL signaled through the two receptors, BCMA and TACI. In rabbits, Env-APRIL induced significantly higher antibody responses against Env compared to unconjugated Env, while the ...

Reinventing the Health Services Researcher.

Reinventing neutron science in Europe.

Erratum: Reinventing tech transfer.

Pfizer joins PD-L1 pursuit.

Identification of the sAPRIL Binding Peptide and Its Growth Inhibition Effects in the Colorectal Cancer Cells.

A proliferation-inducing ligand (APRIL) is a member of the tumor necrosis factor (TNF) super family. It binds to its specific receptors and is involved in multiple processes during tumorigenesis and tumor cells proliferation. High levels of APRIL expression are closely correlated to the growth, metastasis, and 5-FU drug resistance of colorectal cancer. The aim of this study was to identify a specific APRIL binding peptide (BP) able to block APRIL activity that could be used as a potential treatment for colo...

University biotech patenting 2013.

Third-quarter biotech job picture.

Biotech on the bounce in 3Q14.

Public biotech 2013-the numbers.

Benchmarking biotech and pharmaceutical product development.

Erratum: University biotech patenting 2013.

Fourth-quarter biotech job picture.

Fresh from the biotech pipeline-2014.

2014-the biotech bull rages on.

Taiwan biotech buoyed by colossal financings.

Erratum: Public biotech 2013-the numbers.

Big-cap buying bonanza trickles down to small biotech.

Improving biotech education through gamified laboratory simulations.

Small biotech steers HDAC inhibitor to clinic.

Kernel Compositions of Glyphosate-Tolerant and Corn Rootworm-Protected MON 88017 Sweet Corn and Insect-Protected MON 89034 Sweet Corn Are Equivalent to That of Conventional Sweet Corn (Zea mays).

Monsanto Co. has developed two sweet corn hybrids, MON 88017 and MON 89034, that contain biotechnology-derived (biotech) traits designed to enhance sustainability and improve agronomic practices. MON 88017 confers benefits of glyphosate tolerance and protection against corn rootworm. MON 89034 provides protection against European corn borer and other lepidopteran insect pests. The purpose of this assessment was to compare the kernel compositions of MON 88017 and MON 89034 sweet corn with that of a conventio...


Search BioPortfolio:
Loading
Advertisement
Advertisement

PubMed Database Quicklinks